<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-19_08-07-06</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>- Confirm ECOG status, symptoms, goals; if ECOG ≥3 or patient declines systemic therapy, then adjust management from active treatment to best supportive care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]

- Clarify current bleeding, pain, anemia and HGB 74 g/L; if symptomatic or hemodynamically unstable, then adjust management from outpatient planning to urgent transfusion/stabilization. [@20230103|5600862]

- Obtain full molecular/biomarker profile and trial options; if actionable alteration or suitable trial available, then adjust management from standard empiric therapy to biomarker- or trial-driven strategy.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）术后白紫+卡铂化疗6程，末次：2022.8.172022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)MR（2022.07.17）：2022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)肿瘤标志物（2022.10.12）：CA19-9:77.20U/ml↑,CA125:89.60U/ml↑,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(绝经前)↑,ROMA.:36.67%(绝经后)↑。CT（2022.10.25）：肝内多发结节，部分较前新见，转移可能，请结合MR检查。另见肝囊肿同前。MR（2022.10.24）：盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。盆腔系膜多发强化小结节，转移可能。2022.11.10外院血常规：白细胞 2.36，红细胞 3.56，血红蛋白 97，血小板 153外院生化：ALP　105，NA 136，PAB 1242022.11.30外院血常规：白细胞 3.46，红细胞 3.48，血红蛋白 94，血小板 1342022.11.17外院肿瘤指标：CA125　403，Ca153　63.8，Ca199 96.8，Ca724 695肿瘤标志物（2022.12.29）：CA19-9:229.00U/ml↑,CA125:933.00U/ml↑,CA15-3:86.00U/ml↑,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/L↑,ROMA:41.02%(绝经前)↑,ROMA.:85.98%(绝经后)↑。MR（2022.12.30）：盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。右侧髂骨新见强化结节，转移可能。盆腔系膜多发强化小结节同前相仿，转移可能。直肠局部肠壁增厚伴强化。CT（2022.12.30）：肝内多发转移结节，较前增多，部分较前增大。另见肝囊肿同前。脾脏片状影，脾脏梗塞？随访。咨询报告</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6 cycles&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;白紫+卡铂&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian carcinoma with hepatic and pelvic metastatic disease&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;histology&quot;:&quot;首先考虑为透明细胞癌&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;卵巢癌复发&quot;,&quot;site&quot;:&quot;卵巢&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;白紫+卡铂&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml (2022-10-12)&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Debulking surgery + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;45.7&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;161&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;562&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-11-10&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;97&quot;},{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary debulking surgery&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of 白紫+卡铂&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising CA125&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;白紫+卡铂 (6 cycles)&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;(部分+)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;(少弱+)&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;(+/-)&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;(60%+)&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;(灶+)&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;(-)&quot;}],&quot;involvement_sites&quot;:[&quot;intestinal wall full thickness&quot;,&quot;peritoneum (left retroperitoneal tumor)&quot;,&quot;vagina (partial)&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7*4*2.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Molecular/genetic testing not reported&quot;,&quot;Definitive origin laterality not specified&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;sacrum&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Pelvis post-op changes&quot;,&quot;presacral mass, consider recurrence with adjacent sacral involvement&quot;,&quot;multiple enhancing small mesenteric nodules in pelvis, suggest metastases&quot;],&quot;impression&quot;:&quot;Recurrence with possible sacral involvement and pelvic mesenteric metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple hepatic nodules, some new compared to prior&quot;,&quot;hepatic cysts unchanged&quot;],&quot;impression&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;right iliac bone&quot;,&quot;sacrum&quot;,&quot;rectum&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral mass increased in range with heterogeneous enhancement&quot;,&quot;new enhancing nodule in right iliac bone&quot;,&quot;multiple pelvic mesenteric enhancing nodules&quot;,&quot;rectal local bowel wall thickening with enhancement&quot;],&quot;impression&quot;:&quot;Progressive pelvic recurrence with possible peritoneal and sacral involvement; new right iliac bone lesion&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;,&quot;spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size&quot;,&quot;patchy splenic shadow, possible splenic infarct&quot;],&quot;impression&quot;:&quot;Progressive hepatic metastases; splenic abnormality noted, follow-up suggested&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: None
- name: None
- Reason: Primary cancer is ovarian clear cell carcinoma, not cervical cancer as required by all available trials.
- Missing eligibility confirmations (0-2 items):
  - None
  - None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Confirm performance status, symptom burden, and goals of care, then prioritize systemic therapy for platinum‑resistant clear‑cell ovarian carcinoma with rapid progression [@guideline:nccn_ovariancancer_v3_2025__v00000000|22; @pubmed:33758607].  \n\n- Obtain updated labs (including iron studies, renal/hepatic function), address severe anemia (Hgb 74 g/L) and bone/sacral pain, and arrange palliative radiation consult for symptomatic pelvic/osseous disease [@20230103|5600862; @2022-12-29|MR].  \n\n- Ensure comprehensive molecular profiling using recent tumor (beyond current HRD‑negative, BRCA‑wildtype report) to identify trial/targeted options, and discuss enrollment in studies tailored to clear‑cell, platinum‑resistant ovarian cancer [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|15; @pubmed:33758607].&quot;,
  &quot;oncologist&quot;: &quot;- Early biochemical and radiologic relapse (&lt;6 months) after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; consider non‑platinum systemic approach [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Current severe anemia (Hgb 74 g/L) may limit therapy intensity; optimize transfusion/iron and clarify performance status, symptoms, comorbidities [@20230103|2023-01-03].  \n\n- HRD negative, BRCA1/2 wild-type; need updated imaging for disease burden, ECOG, renal function, and prior maintenance/biologic exposure to choose regimen [@OH2203828|2022-04-18].&quot;,
  &quot;radiologist&quot;: &quot;- Progressive presacral pelvic mass with sacral and right iliac bone involvement, plus multiple pelvic mesenteric nodules consistent with recurrent/metastatic disease [@2022-12-29|MR].  \n\n- Increasing number and size of multiple hepatic metastatic nodules; stable hepatic cysts [@2022-12-29|CT].  \n\n- Splenic patchy low-density lesion suspicious for infarct; recommend imaging follow‑up for evolution and complications [@2022-12-29|CT][@pubmed:33758607].&quot;,
  &quot;pathologist&quot;: &quot;- Histology and IHC support diagnosis of ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not specified [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- MMR proteins intact; HRD and BRCA1/2 pathogenic variants not detected; germline ATM p.Y316C reported, clinical significance unclear [@OH2203828|2022-04-18].  \n\n- For future care, comprehensive tumor profiling (MSI, TMB, PD-L1, broader somatic panel) is missing and should be updated [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT available; metabolic burden, sacral/right iliac bone involvement, and splenic lesion characterization remain unknown/needs update.  \n\n- Prior CT/MR show progressive pelvic, hepatic, and possible sacral/right iliac bone metastases, high suspicion for widespread recurrence [@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET/CT could refine current staging, assess extrahepatic/peritoneal/bone disease, and guide radiotherapy or surgery decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic progression [@report_id:2022-12-29|MR; @report_id:2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Obtain updated comprehensive labs (including iron/B12, renal, hepatic, coagulation), manage significant anemia urgently, and rule out contraindications before starting next‑line systemic and bone‑directed/palliative local treatments [@report_id:2023-01-03|5600862].  \n\n- Arrange multidisciplinary review of molecular profile (HRD‑negative, BRCA‑WT, ATM variant) and consider repeat/expanded profiling on recent tissue, then prioritize evidence‑based non‑platinum systemic options and clinical trial enrollment for platinum‑resistant ovarian clear cell carcinoma [@report_id:OH2203828|2022-04-18; @pubmed:33758607].&quot;,
    &quot;oncologist&quot;: &quot;- Urgently optimize supportive care: investigate/transfuse severe anemia [@20230103|2023-01-03], assess ECOG, pain, comorbidities, and clarify goals of care.  \n\n- Obtain updated contrast CT chest/abdomen/pelvis for current extent, then plan palliative radiation to sacral/right iliac lesions and systemic strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- Arrange comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to inform non‑platinum and trial options.&quot;,
    &quot;radiologist&quot;: &quot;- Obtain updated contrast CT chest/abdomen/pelvis to reassess burden since progression on 2022-12-29/30 imaging [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Reserve PET/CT for unresolved questions about sacral/right iliac bone or splenic involvement that would directly modify radiation fields [@2022-12-29|CT].  \n\n- Use updated imaging to guide palliative RT planning for painful presacral/sacral/right iliac lesions, aligning with symptom-directed management in recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].&quot;,
    &quot;pathologist&quot;: &quot;- Urgently document ECOG, detailed symptoms, comorbidities, and evaluate/transfuse for severe anemia before defining any new systemic strategy [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease before radiation or systemic decisions [@report_id_unknown|unknown].  \n\n- Arrange comprehensive tumor profiling on recent tissue or ctDNA (MSI, TMB, PD-L1, broad somatic panel) to inform future options [@OH2203828|2022-04-18].&quot;,
    &quot;nuclear&quot;: &quot;- Prioritize supportive care: document ECOG, symptoms, comorbidities; investigate/transfuse for severe anemia before systemic decisions (Hgb 74 g/L, labs otherwise unknown).  \n\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, sacral/right iliac, and splenic disease before radiation planning [@2022-12-29|MR][@2022-12-29|CT].  \n\n- Reserve PET/CT for situations where CT leaves uncertainty that would meaningfully alter radiation fields or local interventions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Prioritize second-line systemic therapy for platinum-resistant clear cell ovarian carcinoma with visceral and bone metastases; deem surgery/radiation palliative only [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @report_id:2022-12-29|CT].  \n\n- Before finalizing regimen, urgently optimize anemia, assess ECOG, symptoms, and clarify goals; obtain full chemistry, coagulation, and updated pain/thromboembolism status [@report_id:20230103|5600862].  \n\n- Arrange comprehensive survivorship and trial-focused review including prior HRD-negative, BRCA‑wildtype status to consider non‑platinum, anti‑angiogenic, immunotherapy, or trial options in sequencing [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10; @report_id:OH2203828].&quot;,
    &quot;oncologist&quot;: &quot;- Urgently correct anemia (transfusion, iron/B12 workup), complete full labs, document ECOG, symptoms, comorbidities, and goals of care. [@20230103|2023-01-03]  \n\n- Restage with contrast CT chest/abdomen/pelvis, then coordinate palliative radiation for painful pelvic/sacral/right iliac disease and integrate palliative care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- Send comprehensive molecular profiling (MSI, TMB, PD‑L1, broad panel/ctDNA); after optimization, select non‑platinum systemic/clinical‑trial strategy for platinum‑resistant clear cell disease. [@pubmed:33758607]&quot;,
    &quot;radiologist&quot;: &quot;- Obtain updated contrast-enhanced CT chest/abdomen/pelvis to restage since documented progression on Dec 2022 imaging [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Use CT as primary tool for palliative RT planning to presacral/sacral/right iliac lesions; reserve PET/CT for equivocal sites [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Reassess splenic low-density lesion on new CT to distinguish evolving infarct from alternative pathology and guide need for further imaging [@2022-12-29|CT].&quot;,
    &quot;pathologist&quot;: &quot;- Proceed with comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to expand options [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n\n- Maintain diagnosis of ovarian clear cell carcinoma with intact MMR and HRD-/BRCA1/2‑wild type status; ATM p.Y316C remains VUS [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Ensure pathology–radiology correlation on new contrast CT (pelvis, sacrum/right iliac, spleen) to confirm sites for palliative radiation (report_id unknown|unknown).&quot;,
    &quot;nuclear&quot;: &quot;- Continue with updated contrast CT chest/abdomen/pelvis as primary restaging tool to guide palliative radiation planning [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Reserve PET/CT for CT‑equivocal bone or splenic lesions where metabolic clarification would change radiation fields or local procedures [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- No current evidence that PET/CT would alter systemic therapy choice in this established platinum‑resistant, widely metastatic setting [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Ovarian clear cell carcinoma, platinum-refractory after 6 cycles carboplatin-based chemo; metastatic to liver, pelvic/peritoneal, sacrum/right iliac bone; MMR intact (MLH1/MSH2/MSH6/PMS2+); need systemic options and trial eligibility considering prior debulking and good organ function; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6484 nccn_ovariancancer_v3_2025__v00000000 [PAGE 22] [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]
    Survivorship) Recurrent diseaset Hormonal therapyu or Chemotherapy (if not previously used), see OV-C (6 of 12) or Systemic therapyf,v • For platinum-sensitive disease, see OV-C (8 of 12) • For platinum-resistant disease, see OV-C (9 of 12) or Observation f See Principles of Systemic Therapy (OV-C) …
[2] score=0.6446 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]
    n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D). dd Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Tumor molecular analysis is recommended to include, at a minimum, tests to identify potent…
[3] score=0.6396 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …
[4] score=0.6372 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…
[5] score=0.6370 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7047 PMID 35401005 [@pubmed:35401005]
    Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.
    Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The…
[2] score=0.6971 PMID 33758607 [@pubmed:33758607]
    Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
    Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometr…
[3] score=0.6919 PMID 36578942 [@pubmed:36578942]
    Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.
    Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, makin…
[4] score=0.6891 PMID 36591227 [@pubmed:36591227]
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.
    Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radi…
[5] score=0.6773 PMID 30109783 [@pubmed:30109783]
    Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
    NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45 hours and form colonies at high efficiency. They have a very high degree of loss of hetero…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6483736038208008,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 22,
    &quot;text&quot;: &quot;Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\n• For platinum-sensitive disease, see OV-C (8 of 12)\n• For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRα (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6446039080619812,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6396176815032959,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6372156143188477,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6370381712913513,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.704681086648616,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35401005&quot;,
    &quot;title&quot;: &quot;Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The patient received primary cytoreductive surgery with adjuvant chemotherapy and remained disease-free for four months. She then experienced retroperitoneal lymph node recurrence and was treated with liposomal doxorubicin chemotherapy followed by secondary debulking surgery. The patient experienced a second relapse in the lower left lung 11 months later. Genomic profiling of tumor samples revealed a deleterious AT-rich interactive domain 1A (ARID1A) mutation and homologous recombination deficiency. Thus, the triplet combination of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib; the PD-1 inhibitor, pembrolizumab; and the antiangiogenic agent, bevacizumab was administered. The patient achieved partial response, which was sustained for 12 months. Our study provides the first clinical evidence that the combination of olaparib with pembrolizumab and bevacizumab could be an effective treatment for patients with platinum-resistant, recurrent OCCC.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S362267&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.704681086648616
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6971109045400937,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33758607&quot;,
    &quot;title&quot;: &quot;Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrioid carcinoma, which also originates from endometriosis, shares several features with OCCC, including platinum resistance and younger age at diagnosis. Patients with OCCC have about a 2.5 to 4 times greater risk of having a venous thromboembolism (VTE) compared with other EOC, and OCCC tends to metastasize through lymphatic vesicular and peritoneal spread as opposed to hematogenous metastasis. There is only mild elevation of the conventional biomarker CA125. Staging surgery or optimal cytoreduction combined with chemotherapy is a common therapeutic strategy for OCCC. However, platinum resistance commonly portends a poor prognosis, so novel treatments are urgently needed. Targeted therapy and immunotherapy are currently being studied, including PARP, EZH2, and ATR inhibitors combined with the synthetic lethality of ARID1A-dificiency, and MAPK/PI3K/HER2, VEGF/bFGF/PDGF, HNF1β, and PD-1/PD-L1 inhibitors. Advanced stage, suboptimal cytoreduction, platinum resistance, lymph node metastasis, and VTE are major prognostic predictors for OCCC. We focus on update pathogenesis, diagnostic methods and therapeutic approaches to provide future directions for clinical diagnosis and treatment of OCCC.&quot;,
    &quot;journal&quot;: &quot;J Cancer&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.7150/jca.53395&quot;,
    &quot;impact_factor&quot;: 3.2,
    &quot;similarity&quot;: 0.6971109045400937
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6919320547941721,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36578942&quot;,
    &quot;title&quot;: &quot;Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.&quot;,
    &quot;abstract&quot;: &quot;Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, making it impossible to launch large-scale prospective studies and formulate the standard intervention for patients. We herein report a rare case of STO with liver primary cancer metastasis to the ovary and omentum in a 66-year-old woman. The patient underwent debulking surgery with the removal of the uterus, bilateral fallopian tubes, bilateral ovaries, appendix, and a large part of the omentum majus. Next-generation sequencing was conducted after the operation, identifying BRCA2 mutation. Because strongly refusing chemotherapy, she received olaparib as an experimental therapy. After the administration of surgery and olaparib, the serum value of cancer antigen 125 (CA125) and alpha fetoprotein (AFP) decreased dramatically and basically remained within the normal range. So far, she has achieved nearly 2-year survival and lives a relatively normal life with good quality.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2022.1010158&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.6919320547941721
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6890507127734654,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36591227&quot;,
    &quot;title&quot;: &quot;Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radiotherapy and a few cycles of chemotherapy with an extremely durable response even after cessation of immunotherapy for 3 years at the time of publication.&quot;,
    &quot;journal&quot;: &quot;Front Immunol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fimmu.2022.1079253&quot;,
    &quot;impact_factor&quot;: 5.9,
    &quot;similarity&quot;: 0.6890507127734654
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.677342202074444,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;30109783&quot;,
    &quot;title&quot;: &quot;Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.&quot;,
    &quot;abstract&quot;: &quot;NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45 hours and form colonies at high efficiency. They have a very high degree of loss of heterozygosity (LOH) affecting approximately 85% of the genome, mostly copy neutral and almost identical to the original tumor. The cells express epithelial (pan-cytokeratin) and mesenchymal (vimentin) characteristics, CA125 and p16, like the original tumor. They also express ARID1A but not HNF-1β and, like the original tumor, and are negative for p53 expression, with no evidence of p53 function. NUCOLL43 cells express all other DNA damage response proteins investigated and have functional homologous recombination DNA repair. They are insensitive to cisplatin, the PARP inhibitor rucaparib, and MDM2 inhibitors but are sensitive to camptothecin, paclitaxel, and NVP-BEZ235. The NUCOLL43 cell line represents a distinct subtype of O-CCC that is p53 and HNF-1β null but expresses ARID1A. Its high degree of similarity with the original tumor genomically and proteomically, as well as the high level of LOH, make this an interesting cell line for O-CCC research. It has been deposited with Ximbio.&quot;,
    &quot;journal&quot;: &quot;Cancer Med&quot;,
    &quot;pub_date&quot;: &quot;2018-09-01&quot;,
    &quot;doi&quot;: &quot;10.1002/cam4.1724&quot;,
    &quot;impact_factor&quot;: 3.1,
    &quot;similarity&quot;: 0.677342202074444
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- NCCN recommends, for recurrent disease in survivorship, considering hormonal therapy or systemic chemotherapy (per OV-C), with treatment selection guided by platinum sensitivity (platinum-sensitive vs platinum-resistant) and allowing observation as an option in appropriate cases [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  
- NCCN advises validated molecular testing on the most recent available tumor tissue in a CLIA-approved lab, at minimum to identify potentially actionable alterations, to inform systemic therapy and management of drug reactions in ovarian cancer [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  
- ESMO recommends that, in relapse, choice between PARP inhibitors and anti-VEGF therapy should consider histotype, BRCA1/2 mutation status, prior exposure to PARP inhibitors and/or bevacizumab, and cumulative prior platinum, which can affect efficacy and tolerability of re‑treatment [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10].  
- NCCN lists platinum-based chemotherapy as preferred for first recurrence (category 1) in appropriate candidates, with consideration of secondary cytoreductive surgery and best supportive care; immediate platinum-based therapy at recurrence is category 2B and should be individualized [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  
- NCCN notes that definitions of platinum-sensitive versus platinum-resistant disease exist on a continuum and should not be applied rigidly; clinical judgment is emphasized, and data for primary and maintenance therapy in recurrent/persistent low-grade clear cell or low-grade histologies are limited, warranting individualized treatment plans [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  
- Case report evidence suggests that a triplet regimen of olaparib, pembrolizumab, and bevacizumab can induce a remarkable response in third-line treatment of ARID1A-mutated ovarian clear cell carcinoma, supporting consideration of PARP inhibitor–based combinations and immunotherapy/anti-VEGF strategies in selected molecular subsets when standard options are exhausted [@pubmed:35401005].  
- Reviews of ovarian clear cell carcinoma highlight its distinct biology, frequent association with endometriosis, chemoresistance, and lack of standard therapy in recurrence; they support comprehensive molecular profiling (e.g., ARID1A and other targets) and consideration of clinical trial enrollment and non–platinum-based strategies in resistant disease [@pubmed:33758607].  
- A case report of a BRCA2-mutated secondary ovarian tumor originating from liver cancer describes benefit from olaparib, suggesting PARP inhibitors may be considered in BRCA-mutated metastatic adenocarcinomas involving the ovary, even when the primary is extra-ovarian, in the absence of standard options [@pubmed:36578942].  
- Case evidence in clear cell carcinoma of the endometrium shows durable response to pembrolizumab combined with localized radiotherapy, with a possible abscopal effect, supporting the MDT consideration of checkpoint inhibitors plus radiation in selected platinum-refractory clear cell gynecologic cancers, particularly within clinical trials or compassionate-use settings [@pubmed:36591227].  
- Preclinical characterization of the NUCOLL43 ovarian clear cell carcinoma cell line demonstrates high genomic instability and distinct drug sensitivity profiles, underscoring that OCCC may respond differently to cytotoxics and targeted agents than high-grade serous carcinoma, and supporting trial designs that evaluate OCCC-specific therapeutic strategies [@pubmed:30109783].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Guideline+PubMed RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:10.566313&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:10.566765&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;efe856c0897d&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:10.854067&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:16.077482&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:16.082777&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=卵巢癌复发; histology=首先考虑为透明细胞癌; components=高级别腺癌\nPATHOLOGY: 部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\nPLATINUM: status=Resistant; pfi_days=56\nGENETICS: HRD=Unknown; BRCA1=Unknown; BRCA2=Unknown\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; note=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PAL…&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:43.918944&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Ovarian clear cell carcinoma, platinum-refractory after 6 cycles carboplatin-based chemo; metastatic to liver, pelvic/peritoneal, sacrum/right iliac bone; MMR intact (MLH1/MSH2/MSH6/PMS2+); need systemic options and trial eligibility considering prior debulking and good organ function; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:43.918949&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:43.918951&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:43.918953&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:53.245995&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:53.246048&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:57.137244&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 835
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:02:57.137326&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:00.463768&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 590
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:00.463835&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:02.717913&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 454
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:02.717987&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:05.472057&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 518
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:05.472182&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:03:08.059129&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 503
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:04:08.354548&quot;,
    &quot;event&quot;: &quot;evidence_tag_warning&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair/final_round_1&quot;,
      &quot;preview&quot;: &quot;- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic pr…&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:06:22.875859&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2975
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:06:22.878422&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:06:26.359770&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:06:26.359783&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:07:06.807942&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 628
    }
  }
]</pre>
  </details>

</body>
</html>
